EMMA:OTC-Emmaus Life Sciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.1

Change

0.00 (0.00)%

Market Cap

USD 5.36M

Volume

N/A

Analyst Target

USD 24.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

+1.86 (+1.41%)

USD 568.62B
CSLLY CSL Ltd

+0.32 (+0.34%)

USD 89.31B
CMXHF CSL Limited

+4.96 (+2.68%)

USD 89.27B
QSAM Qsam Biosciences Inc

N/A

USD 73.79B
UCBJY UCB SA ADR

-0.74 (-1.11%)

USD 25.10B
UCBJF UCB SA

N/A

USD 25.05B
ARGNF argenx SE

N/A

USD 22.28B
GNMSF Genmab A/S

+10.43 (+3.58%)

USD 19.00B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.48B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.48B

ETFs Containing EMMA

DXF:CA Dynamic Active Global Fin.. 8.59 % 0.86 %

N/A

CAD 0.01B
SXLF:LSE SPDR S&P U.S. Financials .. 6.71 % 0.00 %

+0.36 (+0%)

USD 0.36B
IYJ 6.32 % 0.42 %

N/A

N/A
IVFGC 5.90 % 0.00 %

N/A

N/A
ZFIN:CA 5.14 % 0.00 %

N/A

N/A
BFIN-U:CA 5.12 % 0.00 %

N/A

N/A
LONG:CA CI Global Longevity Econo.. 5.06 % 0.00 %

N/A

CAD 3.53M
ZINN:CA 5.05 % 0.00 %

N/A

N/A
BGU:CA Bristol Gate Concentrated.. 4.92 % 0.85 %

+0.01 (+0%)

CAD 0.11B
FINZ 4.83 % 0.95 %

N/A

N/A
SKF ProShares UltraShort Fina.. 4.83 % 0.95 %

+0.02 (+0%)

USD 0.02B
TPAY 4.68 % 0.00 %

N/A

N/A
ZINT:CA 4.39 % 0.00 %

N/A

N/A
JOYY 4.26 % 0.00 %

N/A

N/A
HAU:CA 4.23 % 0.79 %

N/A

N/A
LINK:CA 4.02 % 0.00 %

N/A

N/A
GBUY Goldman Sachs Future Cons.. 4.00 % 0.00 %

-0.11 (0%)

USD 0.06B
QUAL 3.96 % 0.15 %

N/A

N/A
WBIG WBI BullBear Yield 3000 E.. 3.95 % 1.04 %

N/A

USD 0.05B
UYG ProShares Ultra Financial.. 3.95 % 0.95 %

+0.05 (+0%)

USD 0.68B
HFT:CA 3.89 % 0.00 %

N/A

N/A
QMJ 3.66 % 0.00 %

N/A

N/A
DUAL 3.48 % 0.00 %

N/A

N/A
KEMQ KraneShares Emerging Mark.. 3.17 % 0.80 %

+0.27 (+0%)

USD 0.02B
USMC Principal U.S. Mega-Cap E.. 3.06 % 0.12 %

-0.17 (0%)

USD 2.28B
CMGG:CA CI Munro Global Growth Eq.. 3.03 % 0.00 %

+0.43 (+0%)

CAD 0.04B
HAU-U:CA 3.00 % 0.00 %

N/A

N/A
JHMF 2.96 % 0.47 %

N/A

N/A
UQLT:LSE UBS (Irl) ETF plc - Facto.. 2.94 % 0.00 %

+14.00 (+0%)

USD 0.02B
OPPX 2.37 % 0.00 %

N/A

N/A
VIG Vanguard Dividend Appreci.. 2.30 % 0.06 %

+0.02 (+0%)

USD 77.23B
XDEQ:XETRA Xtrackers MSCI World Qual.. 2.29 % 0.00 %

+0.34 (+0%)

USD 1.47B
CGAA:CA CI Global Asset Allocatio.. 1.91 % 0.00 %

-0.07 (0%)

CAD 0.02B
CAPS:CA 1.85 % 0.96 %

N/A

N/A
RUE-U:CA 1.82 % 0.00 %

N/A

N/A
FLGE 1.79 % 0.00 %

N/A

N/A
XULR:CA 1.72 % 0.00 %

N/A

N/A
USSG Xtrackers MSCI USA ESG Le.. 1.65 % 0.00 %

-0.07 (0%)

USD 1.09B
JQUA JPMorgan U.S. Quality Fac.. 1.64 % 0.12 %

-0.12 (0%)

USD 4.07B
FDLO Fidelity® Low Volatility.. 1.50 % 0.30 %

+0.06 (+0%)

USD 1.05B
BLCK:CA First Trust Indxx Innovat.. 1.42 % 0.81 %

N/A

CAD 1.88M
XESW:LSE Xtrackers (IE) Plc - Xtra.. 1.34 % 0.00 %

+0.16 (+0%)

USD 5.72B
RWCD 1.15 % 0.00 %

N/A

N/A
UIQM:XETRA 0.87 % 0.00 %

N/A

N/A
DVOL First Trust Dorsey Wright.. 0.00 % 0.60 %

+0.08 (+0%)

USD 0.05B
TDV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -68.75% 26% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.75% 26% F 14% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -35.66% 14% F 5% F
Dividend Return -35.66% 14% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.96% 71% C- 57% F
Risk Adjusted Return -87.07% 16% F 7% C-
Market Capitalization 5.36M 44% F 33% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector